

U.S. Department of Commerce Patent and Trademark Office

Serial No. 09/991,603 Atty. Docket No. 29715/35152R Applicant Giroir et al. Group 1654/653 Filing Date

November 23, 2001

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS								
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
AM	A1	5,578,572	11/26/96	Horwitz et al.	514	12		
<u> </u>	A2	5,578,568	11/26/96	Ammons et al.	514	12		
	A3	5,576,292	11/19/96	Elsbach et al.	514	12	<u> </u>	
	A4	5,532,216	07/02/96	Espevik et al.	514	21	CE A	
	A5	5,523,288	06/04/96	Cohen et al.	514	12	1 ER 2 7	
	A6	5,494,896	02/27/96	Hansbrough, J.F.	514	12	2002 1600/2900	
	A7	5,488,034	01/30/96	McGregor et al.	514	12	/290	
	A8	5,484,705	01/16/96	White et al.	435	7.32	8	
	A9	5,466,581	11/14/95	White et al.	435	7.32		
	A10	5,466,580	11/14/95	White et al.	435	7.1		
	A11	5,447,913	09/05/95	Ammons et al.	514	12		
	A12	5,439,807	08/08/95	Grinna, L.S.	435	69.1		
	A13	5,420,019	05/30/95	Theofan et al.	435	69.1		
	A14	5,348,942	09/20/94	Little II, et al.	514	12		
	A15	5,334,584	08/02/94	Scott et al.	514	12		
	A16	5,308,834	05/03/94	Scott et al.	514	12		
	A17_	5,245,013	09/14/93	Ulevitch et al.	530	380		
	A18	5,234,912	08/10/93	Marra et al.	514	21		
\bigvee	A19	5,198,541	03/30/93	Elsbach et al.	435	69.1		
An	A20_	5,171,739	12/15/92	Scott et al.	514	12		

examiner Abdel A.	Mohamed	
		-

DATE CONSIDERED 3/12/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GYPE >			SHEET	2 01 10
Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 29715/35152R	Serial No. 09/991,603	TECH
INFORMATION DISCOURE	STATEMENT	Applicant Giroir et al.		I CENT
(Use several sheets if necessar		Filing Date November 23, 2001	Group 1654/653	ER 160
				202

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Au	A21	5,089,274	02/18/92	Marra et al.	424	534	

FOREIGN PATENT DOCUMENTS									
							Trans	ation	
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Yes	No	
Au	B1	WO 96/21436	07/18/96	PCT			TT C		
	В2	WO 96/08509	03/21/96	PCT				<u> </u>	
	В3	WO 96/01647	01/25/96	РСТ				1 20	
	B4	WO 95/24209	09/14/95	PCT				2 20	
	В5	WO 95/20163	07/27/95	PCT			00/5	2002/	
	В6	WO 95/19784	07/27/95	PCT				B	
	В7	WO 95/19372	07/20/95	PCT					
	В8	WO 95/19180	07/20/95	PCT					
	В9	WO 95/19179	07/20/95	PCT					
	B10	WO 95/10297	04/20/95	PCT					
	B11	WO 95/08773	03/30/95	PCT					
	B12	WO 95/08344	03/30/95	PCT					
	B13	WO 95/02414	01/26/95	PCT c					
V	B14	WO 95/01428	01/12/95	PCT					
AV	B15	WO 95/00641	01/05/95	PCT					

EXAMINER Abdil	A. Mohamed	DATE CONSIDERED
		i i i i i i i i i i i i i i i i i i i

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		10115					SHE	ET 3 of 18	
1					Atty. Docket No. 29715/351:	52R	Serial No. 09/991,60	3	
INFOR	INFORMATION DESCRIPTION OF THE STATEMENT							TEO	
					Filing Date November	23, 2001	Group 1654/65	MAR H CELV	
		FOI	REIGN PATE	ENT DOC	UMENTS			00:25 00:55	
							Trans	lation	
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Yes	No	
m	B16	WO 94/25476	11/10/94	PCT	_				
7	B17	WO 94/21280	09/29/94	PCT			- FT	— —	
	B18	WO 94/20532	09/15/94	PCT					
	B19	WO 94/20129	09/15/94	PCT				2 1	
	B20	WO 94/20128	09/15/94	PCT	-		Į į	ŧ ≃ ≮	
	B21	WO 94/18323	08/18/94	PCT			022	12	
	B22	WO 94/17819	08/18/94	PCT					
	B23	WO 93/23540	11/25/93	PCT			<u> </u>		
	B24	WO 93/06228	04/01/93	PCT					
	B25	WO 93/05797	04/01/93	РСТ					
	B26	WO 93/23434	11/25/93	PCT					
	B27	WO 92/09621	06/11/92	РСТ					
	B28	WO 92/03535	03/05/92	PCT					
<u> </u>	B29	WO 91/01639	02/21/91	PCT					
AM	B30	WO 90/09183	08/23/90	PCT					

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
My	C1	Ammons et al., "Recombinant Amino Terminal Fragment of Bactericidal/ Permeability Increasing Protein Prevents Hemodynamic Responses to Endotoxin", Circulatory Shock, 41(3):176-184 (November, 1993).

EXAMINER	Abdel A.	Mohamed	DATE CONSIDERED	3	12/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\ a	Atty. Docket No. 29715/35152R	Serial No. 09/991,603	HO31
\fig		• • • • • • • • • • • • • • • • • • • •	C 7 "#
INFORMATION DISCLOSURE STATEMENT	Applicant Giroir et al.		ENTE
	Filing Date November 23, 2001	Group 1654-/653	R 1600

	-	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
m	C2	Ammons et al., "Protective Effects of an N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Rodent Models of Gram-Negative Sepsis: Role of Bactericidal Properties," J. Infect. Dis., 170(6):1473-82 (December, 1994).
	C3	Ammons et al., "An N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein Protects against Hemodynamic and Metabolic Derangements in Rat Gram-Negative Sepsis," J. Endotoxin Res., 3(1):57-66 (1996).
	C4	Ammons et al., "Protective Effects of an N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Endotoxemia and Gram-Negative Sepsis," Novel Therapeutics Strategies in the Treatment of Sepsis, pp. 55-70 (1996).
	C5	Baggiolini et al., "Neutrophil-activating Peptide-1/Interleukin 8, a Novel Cytokine That Activates Neutrophils", J. Ciin. Invest., 84:1045-1049 (October, 1989).
	C6	Barron, "Pathophysiology of Septic Shock and Implications for Therapy," <i>Clinical Pharmacy</i> , 12(11):829-845 (November, 1993).
	C7	Berry, L.N., "Introduction" in <i>Handbook of Endotoxin, Volume 3, Cellular Biology of Endotoxin</i> , Berry, L.N., (Ed.), Elsevier, Amsterdam, New York, Oxford, pp. xvii-xxi, (1985).
	C8	Binnema et al., "Quantitation of Urokinase Antigen in Plasma and Culture Media by Use of an Elisa," <i>Thromb. Res, 43</i> :569-577 (1986).
	C9	Bloom et al., "Serum Neopterin Levels Following Intravenous Endotoxin Administration to Normal Humans", <i>Immunobiol.</i> , 181:317-323 (1990).
	C10	Boermeester et al., "Bactericidal/Permeability-Increasing Protein (BPI) Prevents Hemodynamic and Metabolic Derangements Following Partial Hepatectomy," Dutch Society of Gastroenterology Meeting, p. 84 (October 7, 1993) (ABSTRACT).
3	C11	Boermeester et al., "A Prophylactic Approach towards Postoperative Endotoxemia," in Yearbook of Intensive Care and Emergency Medicine 1994, Vincent, J.L., (Ed.), Springer-Verlag, pp. 35-41 (1994).

	EXAMINER AS del A.	Mohamed	DATE CONSIDERED	3/12/03
--	--------------------	---------	-----------------	---------

			SHEET 2 01 18
Form PTO-1449 (Modified) MAR 2 1 2007	U.S. Department of Conumerce Patent and Trademark Office	Atty. Docket No. 29715/35152R	Serial No. 77 09/991,603
INFORMATION PRECLOSURE	' STATEMENT	Applicant Giroir et al.	MAR 2
(Use several sheets if necessar		Fiting Date November 23, 2001	Group ER 2 1654 (6) 65 2
			0,2

		OTHER POOLINE PARTY (*
	T	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
AW	C12	Boermeester <i>et al.</i> "Endotoxin and Interleukin-1 Related Hepatic Inflammatory Response Promotes Liver Failure After Partial Hepatectomy," <i>Hepatology</i> , 22(5):1499-15006 (November, 1995).
	C13	Boermeester et al., "Liver Failure Induces a Systemic Inflammatory Response," Amer. J. Pathology, 147(5):1428-1440 (November, 1995)
	C14	Bone, R.C., "The Pathogenesis of Sepsis," Ann. Inter. Med., 115:457-469 (1991).
	C15	Bone et al., "Definitions for sepsis and organ failure", Critical Care Medicine, 20(6):724-726 (1992).
	C16	Boujoukos et al., "Detection of Interleukin-8 in Bronchoalveolar Lavage Without Alveolar Neutrophil Influx, Beforc and After Intravenous Endotoxin in Normal Humans", Am. Rev. Resp. Dis., 145(4):A441 (April, 1992) (ABSTRACT).
	C17	Boujoukos et al., "Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration", J. Appl. Physiol., 74:3027-3033 (1993).
	C18	Bradley et al., "Hemodynamic Alterations in Normotensive and Hypertensive Subjects During the Pyrogenic Reaction", J. Clin. Invest., 24:749-758 (1945).
	C19	Brandtzaeg <i>et al.</i> , "Plasma Endotoxin as a Predictor of Multiple Organ Failure and Death in Systemic Meningococcal Disease," <i>J. Infect. Dis.</i> , 159(2):195-204 (February, 1989).
	C20	Brandtzaeg et al., "Plasminogen Activator Inhibitor 1 and 2, Alpha-2-Antiplasmin, Plasminogen, and Endotaxin Levels in Systemic Meningococcal Disease," Thrombosis Research, 57:271-278 (1990).
	C21	Brandtzaeg et al., "Meningococcal Endotoxin in Lethal Septic Shock Plasma Studied by Gas Chromatography, Mass-Spectrometry, Ultracentrifugation, and Electron Microscopy," J. Clin. Invest., 89:816-823 (March, 1992).
J	C22	Brandtzaeg, P., "Pathogenesis of Meningococcal Infections," in <i>Meningococcal Disease</i> , K. Cartwright, Ed., John Wiley & Sons, Ltd. pp. 72-114 (1995).
M	C23	Brigham et al., "Endotoxin and Lung Injury", Rev. Respir. Dis., 133:913-927 (1986).

EXAMINER Abdel	A-Mohamed	DATE CONSIDERED	3	12/03
·			,	

U.S. Department of Commerce Patent and Trademark Office

Serial No. 09/991,603 Atty. Docket No. 29715/35152R

Applicant

Filing Date

Giroir et al.

Group 1654 /W November 23, 2001

(Use several sheets if necessary)

	-	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
my	C24	Calandra et al., "Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-1, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock", J. Infect. Diseases, 161:982-987 (May, 1990).
	C25	Calandra et al., "High Circulating Levels of Interleukin-6 in Patients with Septic Shock: Evolution During Sepsis, Prognostic Value, and Interplay with Other Cytokines", Am. J. Medicine, 91:23-29 (July, 1991).
	C26	Cannon et al., "Circulating Interleukin 1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever", J. Infect. Diseases, 161:79-84 (January, 1990).
	C27	Cavaillon, J.M., "Controversies Surrounding Current Therapies for Sepsis Syndrome," <i>Bull. Inst. Pasteur.</i> , 93:21-41 (1995).
	C28	Chmielewska <i>et al.</i> , "Evidence For a Rapid Inhibitor To Tissue Plasminogen Activation in plasma," <i>Thromb. Res.</i> , 31:427-436 (1983).
	C29	Cochrane, "The Enhancement of Inflammatory Injury", Am. Rev. Respir. Dis., 136:1-2 (1980).
	C30	Colman, "Surface-mediated Defense Reactions, The Plasma Contact Activation System", J. Clin. Invest., 73:1249-1253 (May, 1984).
	C31	Cross et al., "Choice of Bacteria in Animal Models of Sepsis," Infect. Immun., 61(7):2741-2747 (July, 1993).
	C32	Cross, A.S., "Antiendotoxin Antibodies: A Dead End?" Ann. Intern. Med., 121(1):58-60 (July 1, 1994).
	C33	Danner et al., "Endotoxemia in Human Septic Shock", Chest, 99:169-175 (January 1991).
	C34	de Winter <i>et al.</i> , "Recombinant Endotoxin-Binding Protein (rBPI ₂₃) Attenuates Endotoxin-Induced Circulatory Changes in Humans," <i>J. Inflamm.</i> , 45:193-206 (1995).
~ ~	C35	De La Cadena <i>et al.</i> , "Activation of the Kallikrein-Kinin System After Endotoxin Administration to Normal Human Volunteers", <i>Blood</i> , 81(12):3313-3317 (June 15, 1993).

	····			 	
EXAMINER	Abdel	A -	Mola	 DATE CONSIDERED	3/12/0

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ADECL AND TO

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

1NFORMATION DISCUSSIVE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 29715/35152R

Applicant Giroir et al.

Filing Date November 23, 2001 Group 1654-63

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
An	C36	Dinarello, C.A., "The Proinflammatory Cytokines Interleukin-l and Tumor Necrosis Factor and Treatment of the Septic Shock Syndrome", <i>J. Infection Diseases</i> , 163:1177-1184 (June, 1991).
	C37	Edwards <i>et al.</i> , "Complications and Sequelae of Meningococcal Infections in Children," <i>J. of Pediatrics</i> , 99(4):540-545 (October, 1981).
	C38	Elin et al., "Effect of Induced Fever on Serum Iron and Ferritin Concentrations in Man", Blood, 49(1):147-153 (January, 1977).
	C39	Elms et al., "Measurement of Crosslinked Fibrin Degradation Products-An Immunoassay Using Monoclonal Antibodies," <i>Thromb. Haemostas</i> , 50(2):591-594 (1983).
	C40	Elsbach et al., "Separation and Purification of a Potent Bactericidal/Permeability Increasing Protein and a Closely Associated Phospholipase A ₂ from Rabbit Polymorphonuclear Leukocytes," <i>J. Biol. Chem.</i> , 254(21):11000-11009 (November, 1979).
	C41	Elsbach and Weiss, "Oxygen-Independent Antimicrobial Systems of Phagocytes," In <i>Inflammation: Basic Principles and Clinical Correlates</i> , Chapter 30, Second Edition, Gallin <i>et al.</i> , (<i>Eds.</i>), Raven Press, Ltd., pp. 603-636, (1992).
	C42	Elsbach et al., "Prospects for Use of Recombinant BPI in the Treatment of Gram- Negative Bacterial Infections," Infect. Agents Dis., 4:102-109 (1995).
	C43	Evans et al., "Protective Effects of a Recombinant Amino-Terminal Fragment of Human Bactericidal/Permeability-Increasing Protein in an Animal Model of Gram-Negative Sepsis," J. Infect. Dis., 171:153-60 (January, 1995).
	C44	Fijnvandraat et al., "Endotoxin Induced Coagulation Activation and Protein C Reduction in Meningococcal Septic Shock," in Bacterial Endotoxins: Basic Science to Anti-Sepsis Strategies, Wiley-Liss, Inc., pp. 247-254 (1994).
\mathrew{\text{\tin}\text{\tin}\\ \text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tetx{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tin}\}\text{\text{\text{\ti}\}\tittt{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\texi}\text{\text{\texi}\tint{\text{\text{\texi}\text{\text{\texi}\text{\text{\texi}\text{\text{\texi}\text{\texitit{\text{\texi}\text{\texitilex{\tiint{\texi{\texi}\text{\texi{\texi{\texi}\tint{\texitit{\texi}\tinz}\t	C45	Fink, M.P., "Adoptive Immunotherapy of Gram-Negative Sepsis: Use of Monoclonal Antibodies to Lipopolysaccharide," <i>Crit. Care.Med. (Supplement)</i> , 21(2):S32-S39 (February, 1993).

DATE CONSIDERED

3/2/03

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
M	C46	Fiser, "Assessing the Outcome of Pediatric Intensive Care," J. Pediatrics, 121:168-174 (1992).
	C47	Fisher <i>et al.</i> , "Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: A placebo-controlled study," <i>Crit. Care Med.</i> , 22(4):553-558 (April, 1994).
	C48	Fisher <i>et al.</i> , "Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results form a Randomized, Doubleblind, Placebo-Controlled Trial," <i>JAMA</i> , 271(23):1836-1878 (June 15, 1994).
	C49	Flaegstad et al., "Factors associated with fatal outcome in childhood meningococcal disease," Acta Paediatr., 84:1137-1142 (1995).
	C50	Fong et al., "Endotoxemia Elicits Increased Circulating β2-IFN/IL-6 in Man", J. Immunology, 142(7):2321-2324 (April 1, 1989).
	C51	Fong et al., "Total Parental Nutrition and Bowel Rest Modify the Metabolic Response to Endotoxin in Humans", Ann. Surg., 210(4):449-457 (October, 1989).
	C52	Fong et al., "The Acute Splanchnic and Peripheral Tissue Metabolic Response to Endotoxin in Humans", J. Clin. Invest., 85:1896-1904 (June, 1990).
	C53	Gazzano-Santoro <i>et al.</i> , "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide," <i>Infect. Immun.</i> , 60(11):4754-4761 (November, 1992).
	C54	Genoff et al., "Extremity Amputations in Meningococcemia-Induced Purpura Fulminans," Plastic Reconstructive Surg., 89(5):878-881 (May, 1992).
	C55	Giroir et al., "Meningococcemia," in Essentials of Pediatric Intensive Care, Second Edition, Volume One, Levin D.L. and Morriss, F.C., Eds., Quality Medical Publishing, Inc., pp. 421-427 (1997)
Sh	C56	Giroir et al., "Shock," in Essentials of Pediatric Intensive Care, Second Edition, Volume One, Levin D.L. and Morriss, F.C., Eds., Quality Medical Publishing, Inc., pp. 280-301 (1997)

					7	
EXAMINER Abdel	A	Mohamed	DATE CONSIDERED	3	12/	03
				$\overline{}$		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			DIILLI 7 UI LU
	partment of Commerce and Trademark Office	Atty. Docket No. 29715/35152R	Serial No. 09/991,603
INFORMATION DISCLOSURE STA	TEMENT	Applicant Giroir et al.	
(Use several sheets if necessary)	A LEWIEN I	Filing Date November 23, 2001	Group 1654/63

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
M	C57	Granowitz <i>et al.</i> , "Production of interleukin-1-receptor antagonist during experimental endotoxaemia", <i>Lancet</i> , 338:1423-24 (December 7, 1991).
	C58	Granowitz et al., "Hematologic and Immunomodulatory Effects of an Interleukin-1 Receptor Antagonist Coinfusion During Low-Dose Endotoxemia in Healthy Humans", Blood, 82(10):2985-2990 (November 15, 1993).
	C59	Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," J. Biol. Chem., 264(16):9505-9509 (June 5, 1989).
	C60	Hack et al., "A Modified Competitive Inhibition Radioimmunoassay for the Detection of C3a Use of ¹²⁵ I-C3 Instead of ¹²⁵ I-C3a", J. Immunol. Meth., 108:77-84 (1988).
	C61	Halstensen et al., "Sequelae One Year After Meningococcal Disease," Acta. Neurol. Scand., 89:139-142 (1994).
	C62	Havens et al., "Trends in Mortality in Children Hospitalized With Meningococcal Infections, 1957-1987," Pediatr. Infect. Dis. J., 8(1):8-11 (1988).
	C63	Hesse et al., "Cytokine Appearance in Human Endotoxemia and Primate Bacteremia", Surg., Gyn. & Obstet., 166:147-153 (February, 1988).
	C64	Hochberg, Y., "A sharper Bonferroni procedure for multiple tests of significance," <i>Biometrika</i> , 75(4):800-802 (1988).
	C65	Hoffman et al., "Endotoxin in Septic Shock," Anesth. Analg., 77:613-624 (1993).
	C66	Holvoet, P. et al., "Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA," <i>Thromb. Haemastasis.</i> , 54(3):684-687 (1985).
	C67	In't Veld., "Effects of the Bactericidal/Permeability-Increasing Protein of Polymorphonuclear Leukocytes on Isolated Bacterial Cytoplasmic Membrane Vesicles", <i>Infect. Immun.</i> , 56(5):1203-1208 (May, 1988).
M	C68	Kelly et al., "Role of the bactericidal permeability-increasing protein in the treatment if gram-negative pneumonia", Surgery, 114(2):140-146 (August, 1993).

EXAMINER Abdel A. Mohamed	DATE CONSIDERED 3 11/03
	the MDED 600. Draw line through

Form PTO-1449 (Modified) MAR 2 1 2002 INFORMATION DISCESSURE STATEMENT

(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 29715/35152R Serial No. 09/991,603

Giroir et al.

Filing Date

November 23, 2001

1654 1653

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) C69 Kindt et al, "Initial recruitment of neutrophils to alveolar structures in acute lung M injury", J. Appl. Physiol., 70:1575-1585 (1991). C70 Kirsch, E. et al., "Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience," Pediatr Infect Dis J., 15(11):967-979 (1996). C71 Koch, G.G., "The Use of Non-Parametric Methods in the Statistical Analysis of the Two-Period Change-Over Design," Biometric, 28:577-584 (1972). Kohn et al., "Protective Effect of a Recombinant Amino-Terminal Fragment of C72 Bactericidal/Permeability-Increasing Protein in Experimental Endotoxemia", J. Infect. Diseases, 168:1307-1310 (November, 1993). Kohn et al., "Role of Endotoxin in Acute Inflammation Induced by Gram-Negative C73 Bacteria: Specific Inhibition of Lipopolysaccharide-Mediated Responses with an Amino-Terminal Fragment of Bactericidal/Permeability-Increasing Protein." Infect. Immun., 63(1):333-339 (January, 1995). Koyama et al., "rBPI23 Attenuates Endotoxin-Induced Cardiovascular Depression in C74 Awake Rabbits," SHOCK, 4(1):74-78 (July, 1995) Kung et al., "Efficacy of a recombinant terminal amino fragment of C75 bactericidal/permeability increasing protein in rodents challenged with LPS or E. coli bacteria," In Bacterial Endotoxins: Basic Science to Anti-Sepsis Strategies, Wiley-Liss, Inc., New York, pp. 255-263 (1994). Kung et al., "Pharmacokinetic Evaluations of rBPI23 in Mice, Rats, and Humans," C76 International Conference on Endotoxemia IV, Amsterdam, The Netherlands, p. 23, (August 17-29, 1993) (ABSTRACT P3). Leach et al., "Prevention of Lethal Endotoxemia by BP23", J. Cell. Chem, (Keystone C77 Symposia, Suppl.) 16(C):172 (February 21 - March 7, 1992) (ABSTRACT CB 412). Lechner et al., "The Recombinant 23-kDa N-Terminal Fragment of C78 Bactericidal/Permeability-Increasing Protein (rBPI23) Decreases Escherichia Coli-Induced Mortality and Organ Injury During Immunosuppression-Related Neutropenia." SHOCK, 4(4):298-306 (October, 1995).

EXAMINER Abdel	A Molamed
----------------	-----------

DATE CONSIDERED

3/12/03

U.S. Department of Commerce Patent and Trademark Office

U.S. Department of Commerce Patent and Trademark Office

29715/35152R

Applicant Giroir et al.

Filing Date November 23, 2001

Group 1654

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
Au	C79	Levi et al., "Reduction of Contact Activation Related Fibrinolytic Activity in Factor XII Deficient Patients," J. Clin. Invest., 88:1155-1160 (October, 1991).
	C80	Levy et al., "Antibacterial 15-kDa Protein Isoforms (p15s) Are Members of a Novel Family of Leukocyte Proteins", J. Biol. Chem., 268(8):6058-6063 (March, 1993).
	C81	Lichtman et al., "Reactivation of Arthritis Induced by Small Bowel Bacterial Overgrowth in Rats: Role of Cytokines, Bacteria, and Bacterial Polymers," Infect. Immun., 63(6):2295-2301 (June, 1995).
	C82	Lin et al., "Protective Effect Of A Recombinant Fragment Of Bactericidal/Permeability Increasing Protein Against Carbohydrate Dyshomeostasis And Tumor Necrosis Factor-α Elevation In Rate Endotoxemia," Biochem. Pharmacol. 47(9):1553-1559 (1994).
	C83	Lin et al., "Protective Effects of a Recombinant N-Terminal Fragment of Bactericidal/Permeability Increasing Protein on Endotoxic Shock in Conscious Rabbits," SHOCK, 2(5):324-331 (November, 1994).
	C84	Lin et al., "Synergistic Effect of a Recombinant N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein and Cefamandole in Treatment of Rabbit Gram-Negative Sepsis," Antimicrobial Agents and Chemotherapy, 40(1):65-69 (January, 1996).
	C85	MacIntyre et al., "E5 Antibody Improves Outcome from Multi-Organ Failure in Survivors of Gram-Negative Sepsis", Critical Care Medicine, S14 (April, 1991).
	C86	Mannion et al., "Separation of Sublethal and Lethal Effects of Polymorphonuclear Leukocytes on Escherichia coli", J. Clin. Invest., 86:631-641 (August 1990).
	C87	Marra et al., "Bactericidal/Permeability-Increasing Protein Has Endotoxin-Neutralizing Activity", J. Immunol, 144(2):662-666 (January 15, 1990).
W.	C88	Marra et al., "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin", J. Immunol., 148(2):532-537 (January 15, 1992).

EXAMINER M 100 N NA 100 DATE CONSIDERED	
real of wordings	2/03

Serial No. 09/991,603

Group 1654-U

(016)		
Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 29715/35152R
INFORMATION DISCLOSERE	CTATEMENT	Applicant Giroir et al.
(Use several sheets if necessa		Filing Date November 23, 2001

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
Any	C89	Marra <i>et al.</i> , "Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5," <i>Crit. Care. Med.</i> , 22(4):559-565 (1994).
	C90	Martich et al., "Detection of Interleukin 8 and Tumor Necrosis Factor in Normal Humans after Intravenous Endotoxin: The Effect of Antiinflammatory Agents", J. Exp. Medicine, 173:1021-1024 (April, 1991).
	C91	Martich et al., "Effects of ibuprofen and pentoxifylline on the cardiovascular response of normal humans to endotoxin", J. Appl. Physiol., 73(3):925-931 (1992).
	C92	Martich et al., "Intravenous Endotoxin Administration to Normal Humans Primes Neutrophils for an Enhanced Respiratory Burst", Critical Care Medicine, S100 (April, 1992).
	C93	Martich et al., "Response of Man to Endotoxin", Immunobiol., 187(3-5):403-416 (April, 1993).
	C94	McManus et al., "Coagulopathy as a Predictor of Outcome in Meningococcal Sepsis and the Systemic Inflammatory Response Syndrome With Purpura," Critical Care Medicine, 21(5):706-711 (1993).
	C95	Meszaros et al., "A Recombinant Amino Terminal Fragment of Bactericidal/Permeability-Increasing Protein Inhibits the Induction of Leukocyte Responses by LPS," J. Leukocyte Biol., 54(6):558-563 (December, 1993).
	C96	Meszaros et al., "Monocyte Tissue Factor Induction by Lipopolysaccharide (LPS): Dependence on LPS-Binding Protein and CD14, and Inhibition by a Recombinant Fragment of Bactericidal/Permeability-Increasing Protein," Blood, 83(9):2516-2525 (May 1, 1994).
	C97	Michie et al., "Detection of Circulating Tumor Necrosis Factor After Endotoxin Administration", N. Eng. J. Medicine, 318(23):1481-1486 (June 9, 1988).
	C98	Moore et al., "A Single Dose of Endotoxin Activates Neutrophils without Activating Complement", Surgery, 102(2):200-205 (August, 1987).
M	C99	Moser et al., "Cardiopulmonary Consequences of Pyrogen-Induced Hyperpyrexia in Man", J. Clin. Invest., 42(5):626-634 (1963).

EXAMINER	f	16 del	A).	N	ohame d	DATE CONSIDERED	3	12/03

DITENT IN OUTO

Form PTO-1449 (Modified) MAR 2 1 2002 INFORMATION DISGLOSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 29715/35152R Serial No. 09/991,603

Applicant

(Use several sheets if necessary)

Giroir et al.

Filing Date

November 23, 2001

1654/653

12/03

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
UN	C100	Nadel et al., "Treatment of Meningococcal Disease in Childhood," in <i>Meningococcal Disease</i> , Cartwright, ed., J. Wiley & Sons, New York, pp. 207-243 (1995).
	C101	Natanson et al., "Role of Endotoxemia in Cardiovascular Dysfunction and Mortality", J. Clin. Invest., 83:243-251 (January, 1989).
	C102	Natanson et al., "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis," Ann. Inter. Med., 120(9):771-783 (May 1, 1994).
	C103	Niklasson et al., "Prognostic Factors in Meningococcal Disease," Scand. J. Infect. Dis., 3:17-25 (1971).
	C104	Nuijens <i>et al.</i> , "Plasma Elastase α_1 -antitrypsin and lactoferrin in sepsis: Evidence for neutrophils as mediators in fatal sepsis", <i>J. Lab. Clin. Med.</i> , 119:159-168 (1992).
	C105	Ooi et al., "A 25-kDa NH ₂ -terminal Fragment Carries All the Antibacterial Activities of the Human Neutrophil 60-kDa Bactericidal/Permeability-increasing Protein," J. Biol. Chem., 262(31):14891-14894 (1987).
	C106	Ooi et al., "Isolation of Two Isoforms of a Novel 15-kDa Protein from Rabbit Polymorphonuclear Leukocytes That Modulate the Antibacterial Actions of Other Leukocyte Proteins," J. Biol. Chem., 265:15956-15962 (September 15, 1990).
	C107	Ooi et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30 KDC-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils," J. Exp. Med., 174:649-655 (September, 1991).
	C108	Parker et al., "Profound but Reversible Myocardial Depression in Patients with Septic Shock," Ann. Intern. Med., 100:483-490 (1984).
	C109	Parker et al., "Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: Heart rate as an early predictor of prognosis," J. Crit. Care., 15(10):923-929 (1987).
Sw.	C110	Parrillo et al., "Septic Shock in Humans", Annals of Int. Med. 113(3):227-242 (August, 1990).

Asal A. Molation	EXAMINER Abdel A. Mohamed DATE	CONSIDERED 7
------------------	--------------------------------	--------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

s +	1000			011111111111111111111111111111111111111
Form PTO-1449 (Modified)	MAR 2 1 2002	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 29715/35152R	Serial No. 09/991,603
INFORMATION DISCLOSURE STATEMENT			Applicant Giroir et al.	
	reral sheets if necessa		Filing Date November 23, 2001	Group 1654 /653

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
m	C111	Peters et al., "Rapid Microanalysis of Coagulation Parameters by Automated Chromogenic Substrated Methods-Application in Neonatal Patients," <i>Thromb. Res.</i> , 28:773-781 (1982).
	C112	Petros et al., "Effects of a Nitric Oxide Synthase Inhibitor in Humans With Septic Shock," Cardiovascular Research, 28:34-39 (1994).
	C113	Pollack et al., "Pediatric Risk of Mortality (PRISM) Score," Critical Care Medicine, 16(11):1110-1116 (November, 1988).
	C114	Powars et al., "Epidemic Meningococcemia and Purpura Fulminans with Induced Protein C Deficiency," Clinical Infectious Diseases, 17:254-261 (1993).
	C115	Pruzanski et al., "Hyperphospholipasemia A ₂ in Human Volunteers Challenged with Intravenous Endotoxin", Inflammation 16(5):561-570 (1992).
	C116	Quezado et al., "A Controlled Trial of HA-1A in a Canine Model of Gram-negative Septic Shock," JAMA. 269(17):2221-2227 (May 5, 1993).
	C117	Quezado et al., "New Strategies for Combating Sepsis: The Magic Bullets Missed the MarkBut the Search Continues," TibTech, 13:56-63 (February, 1995).
	C118	Rackow et al., "Hemodynamic Response to Fluid Repletion in Patients With Septic Shock: Evidence for Early Depression of Cardiac Performance," Circ. Shock, 22:11-22 (1987).
	C119	Revhaug et al., "Inhibition of Cyclo-oxygenase Attenuates the Metabolic Response to Endotoxin in Humans", Arch. Surg. 123:162-170 (February, 1988).
	C120	Scannon, P.J., "Applying Lessons Learned from Anti-Endotoxin Therapy," J. Endo. Res., 2:217-220 (1995).
	C121	Schlag et al., "Protective Effect of Bactericidal/Permeability Increasing Protein (rBPI ₂₁) on Sepsis Induced Organ Failure in Nonhuman Primates," SHOCK Conference, Ashville, N.C. June 11-14, (1995) (ABSTRACT).
SW.	C122	Sheridan <i>et al.</i> , "Management Strategy in Purpura Fulminans with Multiple Organ Failure in Children," <i>Burns.</i> 22(1):53-56 (1996).

EXAMINER A 0 0	A C 0 A . 1	DATE CONSIDERED	7	11/07
<u>175del</u>	A). (Mohamed		_2_1	1405

	/			ULLE LU UL LU
Form PTO-1449 (Modified)	MAR 2 1 2002	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 29715/35152R	Serial No. 09/991,603
INFORMATION I		CTATEMENT	Applicant Giroir et al.	
	everal sheets if necessa		Filing Date November 23, 2001	Group 1654 1653

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
MM	C123	Sinclair et al., "Prognosis of Meningococcal Septicaemia," Lancet, 2:38 (July 4, 1987).		
	C124	Smith et al., "Endotoxin Administration to Normal Humans Causes Increased Alveolar Permeability and Priming of Alveolar Macrophages to Produce Enhanced Superoxide and IL-1 Production", Clin. Res. 36:374A (April, 1988) (ABSTRACT).		
	C125	Spinas <i>et al</i> , "Induction of plasma inhibitors of interleukin 1 and TNF-α activity by endotoxin administration to normal humans", <i>Am. J. Physiol.</i> , 259:R933-R997 (1990).		
	C126	Spinas et al., "Pretreatment with Ibuprofen Augments Circulating Tumor Necrosis Factor-α, Interleukin-6, and Elastase during Acute Endotoxinemia", J. Infectious Dis., 163:89-85 (1991).		
	C127	Steven et al., "The Clinical Spectrum of Meningococcal Disease," in Meningococcal Disease, Cartwright, ed., J. Wiley & Sons, New York, pp. 178-205 (1995).		
	C128	Stiehm & Damrosch, "Factors in the prognosis of meningococcal intection," <i>J. Pediatrics</i> , 68:457-467 (1966).		
	C129	Sturk et al., "Optimalization of a Chromogenic Assay for Endotoxin in Blood," in Bacterial Endotoxins: Structure, Biomedical Significance, and Detection with the Limulus Amebocyte Lysate Test, pp. 117-136 (1985).		
	C130	Suffredini et al., "Promotion and Subsequent Inhibition of Plasminogen Activation after Administration of Intravenous Endotoxin to Normal Subjects", N. Eng. J. Medicine, 320(18):1165-1172 (May 4, 1989).		
	C131	Suffredini et al., "The Cardiovascular Response of Normal Humans to the Administration of Endotoxin", N. Eng. J. Medicine, 321:280-287 (August 3, 1989).		
	C132	Suffredini et al., "Pulmonary and Oxygen Transport Effects of Intravenously Administered Endotoxin in Normal Humans", Am. Rev. Respir. Dis., 145:1398-1403 (1992).		
M	C133	Suffredini, A.F., "Current Prospects for the Treatment of Clinical Sepsis," <i>Crit. Care Med.</i> , 22(7):S12-S18 (July, 1994).		

EXAMINER Abdel A. Mohamed	DATE CONSIDERED	3/12/03

	/		_
Form PTO-1449 (Modified)	MAR 2 1 2802 W	U.S. Department of Commerce Patent and Trademark Office	:
INFORMATIO	ON DISCLOSUI	RE STATEMENT	

(Use several sheets if necessary)

Atty. Docket No.
29715/35152R

Applicant
Giroir et al.

Filing Date
November 23, 2001

Serial No.
09/991,603

Filing Date
November 24, 2001

Serial No.
Se

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
M	C134	Teitel <i>et al.</i> , "Studies of the Prothrombin Activation Pathway Utilizing Radioimmunoassays for the F_2/F_{1+2} Fragment and Thrombin-Antithrombin Complex," <i>Blood</i> , 59(5):1086-1096 (May, 1982).
	C135	Tesoro et al., "Factors Affecting Outcome in Meningococcal Infections," AJDC, 145:218-220 (February, 1991).
	C136	Thornton et al., "Bactericidal/Permeability-Increasing Protein Inhibits Tumor Necrosis Factor Release in Whole Blood in Response to Neisseria Meningitidis and N. Gonorrhoeae," FASEB J., 8(4):A137 (1994) (ABSTRACT 794).
	C137	van Deventer <i>et al.</i> , "Experimental Endotoxemia in Humans: Analysis of Cytokine Release and Coagulation, Fibrinolytic, and Complement Pathways", <i>Blood</i> , 76(12):2520-2526 (December 15, 1990).
	C138-	Van Dueren et al., "Correlation between Proinflammatory Cytokines and Antiinflammatory Mediators and the Severity of Disease in Meningococcal Infections," J. Infect. Dis., 172:433-439 (1995).
	C139	van Leeuwan et al., "Hepatic Failure and Coma After Liver Resection is Reversed by Manipulation of Gut Contents: The Role of Endotoxin," Surgery, 110(2):169-175 (August, 1991).
	C140	Van Zee <i>et al.</i> , "Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor, α <i>in vitro</i> and <i>in vivo</i> ", <i>Proc. Natl. Acad. Sci. USA.</i> , 89:4845-4849 (June, 1992).
	C141	Van Zee et al., "Tumor Necrosis Factor (TNF) Soluble Receptors Protect Against Excessive TNFα During Infection and Injury", Fed. Amer. Soc. Exp. Biol., 6:A1715 (1992) (ABSTRACT 4512).
	C142	VanderMeer et al., "Bactericidal/Permeability-Increasing Protein Ameliorates Acute Lung Injury in Porcine Endotoxemia," J. Infect. Dis., 172(1):2006-14 (May 1994)
M	C143	Verheijen et al., "A Simple, Sensitive Spectrophotometric Assay for Extrinsic (Tissue-Type) Plasminogen Activator Applicable to Measurements in Plasma," Thromb. Haemostas, 48(3):266-269 (1982).

EXAMINER	Abdel	A.	Motamed
		* 1	

DATE CONSIDERED

3/12/03

ı	IJ
ì	
ı	\bigcirc
	Π
	<
	Π
_	

/ 0 11 & 1		U111111111111111
Form PTO-1449 (Modified) WAR 2 1 2002 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 29715/35152R	Serial No. 09/991,603
INFORMATION DESCRIPTION OF STATEMENT	Applicant Giroir et al.	MAR
(Use several sheets if necessary)	Filing Date November 23, 2001	Group 1654 60 5 1
		00/29 [

п		8	
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
MM	C144	von der Möhlen <i>et al.</i> , "Effect of rBPI ₂₃ on Endotoxin-induced Cytokine Release and Leukocyte Changes in Human Volunteers" <i>Clinical Research</i> , 42(2):152A (April, 1994) (ABSTRACT).	
	C145	Waage et al., "The Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock", J. Exp. Med. 169:333-338 (January, 1989).	
	C146	Weiss et al., "Resistance of Gram-negative Bacteria to Purified Leukocyte Proteins", J. Clin. Invest., 65:619-628 (March, 1980).	
	C147	Weiss et al., "The Role of Lipopolysaccharide in the Action of the Bactericidal/Permeability Neutrophil Protein on the Bacterial Envelope", J. Immunol., 132:3109-3115 (June, 1984).	
	C148	Weiss et al., "Cellular and Subcellular Localization of the Bactericldal/Permeability-Increasing Protein of Neutrophils," Blood, 69(2):652-659 (February, 1987).	
	C149	Weiss et al., "Tissue Destruction by Neutrophils", N. Eng. J. Medicine, 320(6):365-376 (February 9, 1989).	
	C150 -	Weiss et al., "Human Bacterial/Permeability-Increasing Protein and a Recombinant NH ₂ -Terminal Fragment Cause Killing of Serum-resistant Gram-negative Bacteria in Whole Blood and Inhibit Tumor Necrosis Factor Release Induced by the Bacteria," J. Clin. Invest., 90:1122-1130 (September, 1992).	
	C151	Wolff, "Biological Effects of Bacterial Endotoxins in Man", J. Infectious Diseases 128(Supplement):S259-S264 (July, 1973).	
	C152	Wong et al., "Meningococcal Infections in Children: As Review of 100 Cases," Pediatr. Infect. Dis. J., 8(4):224-227 (1989).	
	C153	Yao et al., "Pathogenesis of Hemorrhage-Induced Bacteria/Endotoxin Translocation in Rats," Annals Surg., 221(4):398-405 (April, 1995).	
	C154	Yong et al., "An Experiment Mouse Model of Yersinia-induced Reactive Arthritis," Microbial Path., 4:305-310 (1988).	
AN	C155	Yong et al., "Protective Effect of Re-LPS Antiserum on Experimental Multiple System Organ Failure," Chinese Medical Journal, 105(10):833-838 (October, 1992).	

EXAMINER	Abler_	A.	Motramed
----------	--------	----	----------

DATE CONSIDERED



		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
MM	C156	C156 Zabel et al., "Oxpentifylline in Endotoxaemia", Lancet. 2:1474-1477 (December 23/30, 1989).		
	C157	Kartalija et al., "Effect of Recombinant N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein (rBPI-23) on Cerebrospinal Fluid Inflammation Induced by Endotoxin," <i>J. Infectious Diseases</i> , 171(4):948-953 (April, 1995).		
	C158	Kirch et al., "Phase I/II Trial of rBPI-21 (A Recombinant 21kD Fragment of Bactericidal/Permeability-Increasing Protein) in Children With Severe Meningococcemia," Pediatric Research, 41(4):35A (April, 1997).		
	C159~	Thornton et al., The FASEB Journal, Volume 8, No. 4, March 15, 1994, Abstract No. 794, page A137.		
	C160	Marijke <i>et al.</i> , Blood, Volume 85, No. 2, pp. 3437-3443, June 15, 1995.		
PM	C161	Marijke et al., The Journal of Infectious Diseases, Volume 172, pp. 144-151, July 1995.		

EXAMINER Abdel A. Mohamed

DATE CONSIDERED

3/12/0=